Royalty Pharma is a diversified pharma-royalty cash machine — it owns synthetic and acquired royalty streams on 35+ blockbuster drugs (Trikafta, Tremfya, Evrysdi, Trodelvy, Xtandi). No labs, no factories, just contractual cash flow at an ~84% operating margin. Four straight beats, an active $3.0B buyback (≈$1.3B used, $1.7B remaining), and a very low 0.42 beta make it a rare quality-value-dividend triple. At $52.96 it has pulled back below the EMA20 ($54.14) but holds above the EMA50 ($52.08) — a buy-the-dip candidate if EMA50 support holds, with R/R improved to 4.44.RP Q1 2026· mai 2026
Royalty Pharma is the largest buyer of biopharmaceutical royalties in the world. Instead of discovering or manufacturing drugs, it buys the royalty streams attached to blockbuster therapies — either from inventors and academic institutions or via "synthetic" royalties funded directly to developers. The result is a diversified, asset-light portfolio of royalties on 35+ commercial products plus 19 development-stage candidates, spanning cystic fibrosis (Vertex's Trikafta/Alyftrek), immunology (J&J's Tremfya), neuroscience (Roche's Evrysdi, Biogen's Spinraza) and oncology (Gilead's Trodelvy, Pfizer/Astellas' Xtandi).RP IR· mai 2026
The economics are unusual and powerful: with almost no operating costs, the company converts royalty receipts into cash at an ~84% operating margin. Q1 2026 Royalty Receipts grew 13% to $887M, led by Tremfya, Voranigo and Evrysdi (partly offset by generic erosion on Promacta). The single risk that matters is capital deployment — growth depends on Royalty Pharma's ability to keep acquiring high-quality streams at attractive prices, and on the patent longevity of its top drugs.RP Q1 2026· mai 2026
| Metric | Value | Signal |
|---|---|---|
| Revenue (FY2025) | $2.38B | Royalty receipts +13% Q1 |
| Adj. EBITDA (Q1 2026) | $889M | ~$3.5B annualized |
| Gross Margin | ~95% | Royalty model |
| Operating Margin | ~84% | Exceptional |
| Net Margin (FY2025) | ~32% | $771M net income |
| Portfolio Cash Flow (FY2025) | $2.7B | Cash machine |
| 2026 Portfolio Receipts Guide | $3.325B – $3.45B | Raised at Q1; +3% to +8% royalties |
| Fwd P/E | 9.4x | Value |
| P/B | 3.53x | Fair (book $15.53) |
| PEG | 0.98 | Attractive (growth-adjusted) |
| Analyst Target (range) | $50 – $66 | Strong Buy · ~$51 avg, Citi high $66 |
This is the part that separates a quality compounder from a value trap. There is no equity-raise dilution — no active ATM, no S-3 equity offering, no convertibles, no toxic financing. Capital is being returned: in January 2025 the board authorized a $3.0B buyback, of which roughly $1.3B has been deployed and ~$1.7B remains as of 31 Mar 2026 — that first $1.23B tranche retired ~37.4M shares (~8.5% of the count), and weighted-average diluted shares actually fell ~4% year-over-year to ~557M in Q1 2026. The two real (but bounded) dilution vectors are: (1) the May 2025 internalization of the external manager (RP Management), a ~$1.1B deal funded mostly in ~24.5M RPRX shares (≈4% of the count) that vest over 5–9 years — a one-off, already-disclosed stock-funded acquisition, not a recurring equity tap; and (2) share-based compensation — ~$122M of SBC in Q1 2026, plus ~$716M of unrecognized comp (Class E interests + Employee EPAs). Even after both, the buyback wins: net of repurchases vs. SBC + manager vesting, the diluted share count is shrinking, not growing.RPRX 10-Q Q1 2026· mai 2026
No active ATM, no S-3 equity raise, no convertibles, no toxic financing. Capital is returned via an active $3.0B buyback ($1.7B remaining) plus a four-year rising dividend. Two bounded caveats: the May 2025 manager internalization was funded mostly in ~24.5M vesting shares (≈4%, a disclosed one-off), and ongoing share-based comp (~$122M/qtr, ~$716M unrecognized) — material but not the death-spiral kind. Net of buyback vs. both, the diluted share count actually fell ~4% YoY, so the float is shrinking, not flat.SEC EDGAR· 2026
| RSI (14) | 50.1 |
| EMA 20 | $54.14 |
| EMA 50 | $52.08 |
| EMA 200 | $44.76 |
| MACD | 0.720 |
| Signal | 1.040 |
| ATR (14) | $1.32 |
The bullish EMA stack is partially broken: price ($52.96) has dropped below the EMA20 ($54.14) but remains above the EMA50 ($52.08) and well above EMA200 ($44.76). RSI at 50.1 is neutral — no longer in the momentum zone but not oversold either. MACD (0.72) has crossed below its signal line (1.04), confirming a bearish crossover and weakening short-term momentum. The key level to watch is EMA50 ($52.08) — a hold there would set up a buy-the-dip entry with significantly improved risk/reward. A daily close below EMA50 would break the medium-term trend structure.Finviz· live
A diversified, cash-generative, low-beta royalty model with a clean balance-sheet narrative. The genuine risks are structural — drug concentration / patent cliffs, deal-pacing, and rate sensitivity of the royalty NPV — rather than dilution or solvency.
Three structural risks (concentration, deal pace, rates) are genuine but diluted across 35+ drug streams and offset by a fortress cash flow profile. There is no equity-raise dilution and no solvency risk (the only dilution vector is moderate share-based comp, partly offset by the active buyback), plus a very low 0.42 beta. This is about as low-drama as healthcare exposure gets — the reason it earns a defensive-diversifier role rather than a speculative one.RP Q1 2026· mai 2026
The pullback to $52.96 has paradoxically improved the trade setup. With the original $54.50 limit never filled (stock declined before reaching it from below), a new entry near $52.50–$53.00 offers significantly better R/R. The stop remains at $51.60, just below the EMA50 ($52.08) — a structural break — for only ~$1.40 of risk. TP1 at $59.00 gives ~$6.00 of reward, yielding a R/R of ~4.44, far superior to the original 1.55. The trade-off is weaker momentum: RSI at 50 (neutral), MACD bearish crossover, and price below EMA20. The thesis depends on EMA50 ($52.08) holding as support — a daily close below it invalidates the setup. Quality fundamentals (4/4 beats, Fwd PE 9.4x, beta 0.42, 1.77% yield) remain fully intact.Targets / Yahoo· 2026
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, SEC EDGAR, Royalty Pharma investor relations, and public market data. Accuracy is not guaranteed.